X4 pharmaceuticals, inc (ASNS)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
License revenue

3,000

-

-

-

0

-

-

-

-

-

-

-

-

Operating expenses:
Research and development

8,911

7,065

8,589

8,854

5,655

4,689

6,158

4,755

4,744

-1,832

10,601

3,906

4,391

General and administrative

4,670

3,914

4,383

4,560

4,783

3,365

2,387

1,621

1,366

-448

2,455

1,738

1,436

Loss on transfer of nonfinancial assets

-

-

-4,000

-

-

-

0

-

-

-

-

-

-

Total operating expenses

13,581

10,875

16,976

13,414

10,438

8,054

8,545

6,376

6,110

-2,280

13,056

5,644

5,827

Loss from operations

-10,581

-10,875

-16,976

-13,414

-10,438

-8,054

-8,545

-6,376

-6,110

2,280

-13,056

-5,644

-5,827

Other expense:
Interest income

296

270

464

394

69

49

51

67

69

-

90

-

-

Grant and incentive income

-

-

-

-

-

-

-

-

-

-

1,618

862

700

Interest expense

584

548

688

512

399

236

148

167

169

-1,316

343

444

1,019

Change in fair value of preferred stock warrant liability

0

0

0

0

288

3,134

-45

-283

592

-

-5

-11

-

Change in fair value of derivative liability

0

0

0

0

183

322

-5

159

-565

-856

0

0

762

Other income

41

316

52

149

0

-

0

-

-

-57

86

-28

-1

Loss on extinguishment of debt

-162

-

-566

-

0

-

0

-

-

-

-

-462

-

Total other expense, net

-409

38

-738

31

-435

-3,228

-57

342

-1,257

-1,584

1,456

-61

442

Loss before provision for income taxes

-10,990

-

-

-

-10,873

-

-

-

-

-

-

-

-

Provision for income taxes

148

-

-

-

0

-

-

-

-

-

-

-

-

Net loss

-11,138

-10,837

-17,714

-13,383

-10,873

-11,282

-8,602

-6,034

-7,367

696

-11,600

-5,705

-5,385

Accruing dividends on Series A convertible preferred stock

0

0

0

0

592

756

756

748

740

-

-

-

-

Adjustment to accumulated deficit in connection with repurchase of Series Seed convertible preferred stock

-

-

0

-

-

-

0

22

-

-

-

-

-

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

16

13

7

Net loss attributable to common stockholders

-11,138

-10,837

-17,714

-13,383

-11,465

-12,038

-9,358

-6,804

-8,107

-2,268

-11,616

-5,718

-5,392

Net loss per share attributable to common stock holders—basic and diluted (usd per share)

-0.56

4.28

-1.22

-1.02

-6.67

-26.23

-20.39

-14.83

-17.70

-10.36

-22.60

-11.13

-10.49

Weighted average common shares outstanding—basic and diluted (in shares)

20,014

16,662

14,562

13,177

1,718

460

459

458

457

290

513

513

513

Net loss

-11,138

-

-

-

-10,873

-

-

-

-

-

-

-

-

Currency translation adjustments

0

-

-

-

23

-

-

-

-

-

-

-

-

Total comprehensive loss

-11,138

-

-

-

-10,850

-

-

-

-

-

-

-

-